10x Genomics (NASDAQ:TXG) PT Lowered to $32.00 at Canaccord Genuity Group

10x Genomics (NASDAQ:TXG – Free Report) had its price target trimmed by Canaccord Genuity Group from $50.00 to $32.00 in a research note published on Tuesday, Benzinga reports. The firm currently has a buy rating on the stock. A number of other brokerages have also recently commented on TXG. Barclays reduced their target price on […]

Leave a Reply

Your email address will not be published.

Previous post Ovid Therapeutics Inc. (NASDAQ:OVID) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Next post JPMorgan Chase & Co. Boosts Texas Capital Bancshares (NASDAQ:TCBI) Price Target to $70.00